DRUG
Synthetic Human Secretin in Children With Autism
Status
Completed
Phase
Phase 3
Enrollment
—
Locations
15
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
May 9, 2002
Study start
Apr 2002
Primary completion
Not reported
Study completion
Jan 2004
Results posted
Not reported
Registry updated
Aug 5, 2005
Outcomes
What the study measures.
Primary outcomes
Not reported in the indexed record.
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 32 Months
- Maximum age
- 59 Months
- Sex
- ALL
- Healthy volunteers
- No
Autism
Study locations
15 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Southwest Autism Research Center
Phoenix, Arizona, United States
UCLA Pediatric Neurology
Los Angeles, California, United States
Children's Hospital and Research Center at Oakland
Oakland, California, United States
1st Allergy & Clinical Research Center
Centennial, Colorado, United States
Alachua Family Psychiatry
Gainesville, Florida, United States
Miami Children's Hospital
Miami, Florida, United States
Riley Children's Hospital
Indianapolis, Indiana, United States
The Clinical Trials Center:A Division of Children's Hospital
Metairie, Louisiana, United States
Hardy Healthcare Associates
Hingham, Massachusetts, United States
Children's Hospital of Michigan
Detroit, Michigan, United States
University of Medicine and Dentistry of New Jersey
Newark, New Jersey, United States
Schneider Children's Hospital
New Hyde Park, New York, United States
The Ohio State University
Columbus, Ohio, United States
Children's Biomedical Center of Utah
Sandy City, Utah, United States
Puget Sound Neurology
Edmonds, Washington, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Secretin.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects
Mayo Clinic · Exocrine Pancreatic Insufficiency · Chronic Pancreatitis
Phase 4
Recruiting
24
2026-07
Secretin in Ex-situ Liver Perfusion
Erasmus Medical Center · Liver Transplantation
Phase 1 / Phase 2
Enrolling by invitation
20
2026-06
Imaging Biomarkers of Pancreatic Function and Disease
Children's Hospital Medical Center, Cincinnati · Pancreatitis · Diabetes Mellitus
Phase 4
Enrolling by invitation
195
2026-03
Secretin in Refeeding
University of California, Los Angeles · Anorexia in Adolescence
Not applicable
Recruiting
10
2026-02
Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies
M.D. Anderson Cancer Center · Pancreatitis
Not applicable
Recruiting
2,345
2025-10
The Cancer of the Pancreas Screening-5 CAPS5)Study
Johns Hopkins University · Pancreas Cancer · Peutz-Jeghers Syndrome (PJS)
Phase 3
Recruiting
9,000
2025-10
The Effects of Bariatric Surgeries on Glucose Metabolism
The University of Texas Health Science Center at San Antonio · Post Bariatric Surgery · Gastric Bypass
Early Phase 1
Recruiting
200
2025-09
The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
Adenocyte, LLC · IPMN, Pancreatic · Pancreas Cancer
Not applicable
Enrolling by invitation
500
2025-03
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.